IP
NTLA icon

Intellectus Partners’s Intellia Therapeutics NTLA Stock Holding History

Intellectus Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$925K Buy
54,675
+200
+0.4% +$2.8K 0.16% 150
2026
Q1 		$698K Buy
54,475
+3,350
+7% +$42.7K 0.14% 167
2025
Q4 		$460K Sell
51,125
-35,850
-41% -$494K 0.09% 201
2025
Q3 		$1.5M Buy
86,975
+1,000
+1% +$12.3K 0.29% 92
2025
Q2 		$806K Buy
85,975
+3,150
+4% +$25.9K 0.17% 147
2025
Q1 		$589K Buy
82,825
+8,300
+11% +$83.8K 0.15% 171
2024
Q4 		$869K Buy
74,525
+15,700
+27% +$245K 0.19% 143
2024
Q3 		$1.21M Buy
58,825
+600
+1% +$13.8K 0.31% 97
2024
Q2 		$1.3M Buy
58,225
+1,225
+2% +$29.2K 0.36% 77
2024
Q1 		$1.57M Buy
57,000
+1,350
+2% +$37.5K 0.41% 70
2023
Q4 		$1.7M Buy
55,650
+4,900
+10% +$141K 0.49% 59
2023
Q3 		$1.6M Sell
50,750
-650
-1% -$25.2K 0.51% 53
2023
Q2 		$2.1M Buy
51,400
+5,135
+11% +$208K 0.63% 40
2023
Q1 		$1.72M Buy
46,265
+600
+1% +$23.5K 0.54% 51
2022
Q4 		$1.59M Buy
45,665
+3,700
+9% +$176K 0.55% 53
2022
Q3 		$2.35M Sell
41,965
-1,260
-3% -$78.2K 0.84% 29
2022
Q2 		$2.24M Sell
43,225
-1,225
-3% -$62.2K 0.77% 29
2022
Q1 		$3.23M Sell
44,450
-3,075
-6% -$261K 0.96% 19
2021
Q4 		$5.62M Sell
47,525
-3,425
-7% -$429K 1.43% 11
2021
Q3 		$6.83M Buy
50,950
+2,300
+5% +$348K 1.65% 9
2021
Q2 		$7.88M Sell
48,650
-22,975
-32% -$1.79M 1.78% 8
2021
Q1 		$4.61M Buy
71,625
+5,700
+9% +$383K 1.27% 13
2020
Q4 		$3.59M Buy
65,925
+20,275
+44% +$736K 1.07% 18
2020
Q3 		$908K Buy
+45,650
New +$952K 0.34% 88

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Intellectus Partners's NTLA Position: Q2 2026 in Review

Intellectus Partners increased its Intellia Therapeutics (NTLA) stake by 0.37% in Q2 2026, buying an estimated $2.8K and bringing the position to 54,675 shares worth $925K. The position accounts for 0.16% of the portfolio, ranked #150.

Intellectus Partners first reported a position in NTLA in Q3 2020 and has held it in 24 quarters since. The position peaked at $7.88M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Intellectus Partners held 54,675 shares of Intellia Therapeutics worth $925K as of Q2 2026.
  • Intellectus Partners bought 200 Intellia Therapeutics shares in Q2 2026, an estimated $2.8K.
  • Intellia Therapeutics made up 0.16% of Intellectus Partners's portfolio in Q2 2026, its #150 holding.
  • Intellectus Partners first reported a position in Intellia Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Intellectus Partners's Intellia Therapeutics position peaked at $7.88M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.